These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16565744)

  • 1. Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist.
    Funke VA; de Medeiros CR; Setúbal DC; Ruiz J; Bitencourt MA; Bonfim CM; Neto JZ; Pasquini R
    Bone Marrow Transplant; 2006 May; 37(10):961-5. PubMed ID: 16565744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease.
    Schmidt-Hieber M; Fietz T; Knauf W; Uharek L; Hopfenmüller W; Thiel E; Blau IW
    Br J Haematol; 2005 Aug; 130(4):568-74. PubMed ID: 16098072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation.
    Massenkeil G; Rackwitz S; Genvresse I; Rosen O; Dörken B; Arnold R
    Bone Marrow Transplant; 2002 Dec; 30(12):899-903. PubMed ID: 12476283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basiliximab for the treatment of steroid-refractory acute graft-versus-host disease after unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation.
    Wang JZ; Liu KY; Xu LP; Liu DH; Han W; Chen H; Chen YH; Zhang XH; Zhao T; Wang Y; Huang XJ
    Transplant Proc; 2011 Jun; 43(5):1928-33. PubMed ID: 21693302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic effects of interleukin-2 receptor antagonists against graft-versus-host disease following unrelated donor peripheral blood stem cell transplantation.
    Fang J; Hu C; Hong M; Wu Q; You Y; Zhong Z; Li W; Zou P; Hu Y; Xia L
    Biol Blood Marrow Transplant; 2012 May; 18(5):754-62. PubMed ID: 21963619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humanized anti-CD25 monoclonal antibody for prophylaxis of graft-vs-host disease (GVHD) in haploidentical bone marrow transplantation without ex vivo T-cell depletion.
    Chen HR; Ji SQ; Wang HX; Yan HM; Zhu L; Liu J; Xue M; Xun CQ
    Exp Hematol; 2003 Nov; 31(11):1019-25. PubMed ID: 14585364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological effects in patients with steroid-refractory graft-versus-host disease following treatment with basiliximab, a CD25 monoclonal antibody.
    Chakupurakal G; García-Márquez MA; Shimabukuro-Vornhagen A; Theurich S; Holtick U; Hallek M; Scheid C; von Bergwelt-Baildon M
    Eur J Haematol; 2016 Aug; 97(2):121-7. PubMed ID: 26492560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of severe intestinal acute graft-versus-host disease with CD25 monoclonal antibody in haploidentical hematopoietic stem cell transplantation].
    Chen HR; He XP; Yang K; Lou JX; Liu XD; Guo Z; Chen P; Liu B
    Zhonghua Yi Xue Za Zhi; 2010 Oct; 90(38):2693-6. PubMed ID: 21162899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [CD25 monoclonal antibody for GVHD prophylaxis in non-T-cell depleted haploidentical bone marrow transplantation for treatment of childhood leukemia].
    Chen HR; Ji SQ; Yan HM; Wang HX; Liu J; Xue M; Zhu L
    Zhonghua Er Ke Za Zhi; 2004 Apr; 42(4):294-8. PubMed ID: 15157394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
    Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of acute grade IV skin and eye graft-versus-host disease by anti-interleukin-2 receptor monoclonal antibody in genoidentical bone marrow transplantation setting.
    Ozşahin H; Tuchschmid P; Lauener R; Waldvogel K; Nadal D; Seger RA
    Turk J Pediatr; 1998; 40(2):231-5. PubMed ID: 9677728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of steroid-resistant acute graft-versus-host disease with an anti-IL-2-receptor monoclonal antibody (BT 563) in children who received T cell-depleted, partially matched, related bone marrow transplants.
    Herbelin C; Stephan JL; Donadieu J; Le Deist F; Racadot E; Wijdenes J; Fischer A
    Bone Marrow Transplant; 1994 May; 13(5):563-9. PubMed ID: 8054909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of anti-CD25 monoclonal antibody used in treating steroid-resistant acute graft-versus-host disease following haploidentical bone marrow transplantation].
    Liu J; Wang HX; Duan LN; Yang HM; Xue M; Zhu L; Ding L; Wang ZD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):160-3. PubMed ID: 19236770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-
    Shen MZ; Li JX; Zhang XH; Xu LP; Wang Y; Liu KY; Huang XJ; Hong SD; Mo XD
    Front Immunol; 2021; 12():749266. PubMed ID: 34621279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
    Brennan DC; Daller JA; Lake KD; Cibrik D; Del Castillo D;
    N Engl J Med; 2006 Nov; 355(19):1967-77. PubMed ID: 17093248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chimeric anti-CD25 monoclonal antibody for treating acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation].
    Wang JZ; Liu KY; Xu LP; Liu DH; Chen YH; Huang XJ
    Zhonghua Nei Ke Za Zhi; 2008 Nov; 47(11):923-5. PubMed ID: 19080235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial data on basiliximab in critically ill children undergoing heart transplantation.
    Ford KA; Cale CM; Rees PG; Elliott MJ; Burch M
    J Heart Lung Transplant; 2005 Sep; 24(9):1284-8. PubMed ID: 16143246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of severe steroid-refractory graft-versus-host disease with IL-2R alpha chain (CD25) monoclonal antibody].
    Lu J; Xu LP; Huang XJ; Chen H; Zhang YC; Ren HY; Guo NL; Lu DP
    Zhonghua Yi Xue Za Zhi; 2003 Feb; 83(3):216-9. PubMed ID: 12812665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients.
    Vafadari R; Quaedackers ME; Kho MM; Mol WM; Chan G; Weimar W; Baan CC
    Transplantation; 2012 Sep; 94(5):465-72. PubMed ID: 22960764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloablative haploidentical hematopoietic stem cell transplantation using basiliximab for graft-versus-host disease prophylaxis.
    Huang R; Tu S; Deng L; Kang Q; Song C; Li Y
    Hematology; 2015 Jul; 20(6):313-9. PubMed ID: 25321657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.